Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). METHODS: In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks. The results of a planned interim analysis conducted at week 72 involving the first 800 patients are reported here (part 1). The primary end points for part 1 were the resolution of steatohepatitis without worsening of liver fibrosis and reduction in liver fibrosis without worsening of steatohepatitis. RESULTS: Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001). A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001). Results for the three secondary outcomes that were included in the plan to adjust for multiple testing were as follows: combined resolution of steatohepatitis and reduction in liver fibrosis was reported in 32.7% of the patients in the semaglutide group and in 16.1% of those in the placebo group (estimated difference, 16.5 percentage points; 95% CI, 10.2 to 22.8; P<0.001). The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo (estimated difference, -8.5 percentage points; 95% CI, -9.6 to -7.4; P<0.001). Mean changes in bodily pain scores did not differ significantly between the two groups. Gastrointestinal adverse events were more common in the semaglutide group. CONCLUSIONS: In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT04822181.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent study reported significant effects on the resolution of MASLD without worsening of fibrosis, but also significant improvements in fibrosis without worsening of MASLD after 72 weeks of treatment with semaglutide.84”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [84]
In the citing paper
“Part 1 of a phase III trial investigating semaglutide for the treatment of MASH demonstrated resolution of steatohepatitis with no worsening of fibrosis in 63% of the semaglutide group, compared with 34% in the placebo group (68).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“In addition, 37% of the semaglutide group showed improvement in fibrosis without worsening of steatohepatitis, compared with 23% in the placebo group.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“As for resmitirom, semaglutide is indicated for MASH patients with moderate to advanced liver fibrosis, but not liver cirrhosis (53).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [53]
In the citing paper
“In the ESSENCE phase 3 trial, semaglutide showed a significant antifibrotic effect in patients with MASH and stage F2–F3 fibrosis (225).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [225]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citationNon-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Self-citationRinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 801–900 of 1,000
Туркина, С. В. (2026) · Consilium Medicum · doi:10.26442/20751753.2026.5.203661
Dasarathy, S., Mitchell, E. P., Wilson, L. A., Neuschwander‐Tetri, B. A., Chalasani, N., Clark, J. M., Diehl, A. M., Hameed, B., Loomba, R. S., Yuan, L., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001797 · Cited by 2
Self-citationSoyaltın, U. E., Aliyeva, N. A., Balta, C., Celebi, T., & Şimşir, İ. Y. (2026) · Ege Tıp Dergisi · doi:10.19161/etd.1885126
Ajmera, V. H., & Loomba, R. S. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70782
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
“…rates of steatohepatitis resolution without fibrosis worsening, while emerging incretin-based co-agonists such as tirz-epatide and glucagon/GLP-1 dual agonists may further enhance histologic response rates in biopsy-confirmed MASH, including patients with moderate-to-advanced fibrosis [130, 141].”
InfluentialDepletion of NAT10 in T cells attenuates metabolic dysfunction–associated steatohepatitis in mice
Yang, Y., Lu, J., Ma, M., Zhou, J., Wang, E., Lu, Y., Dai, Z., Zhou, B., & Li, Y. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000973
“[4,5] For instance, while resme-tirom significantly improved MASH resolution, the absolute response rates remain modest.”
Adiposopathy-Based Chronic Diseases and Therapeutic Role of Semaglutide
Tiwari, A., Pahuja, V., Vipin, V. P., Erande, S. G., Indurkar, S. A., Kumar, A., Saha, I., Lahiri, K. D., Kishore, R., Alok, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_21_26
Advances in the non-invasive assessment of metabolic dysfunction-associated steatotic liver disease
Su, N., Zhou, D., & Fan, J. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.119
Badgandi, M., Srinath, A., Mandora, V., Kandar, D. K., Shukla, P., PUNATAR, D. H., Jain, V., Kumar, S., Girish, P., Budhwar, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_20_26
Semaglutide for Organ Protection
Kharb, S., Bhattacharjee, B., Karuppan, A., V, Khaire, S. S., Routray, P., Ganta, S., Pakhale, K., Pareek, R., Matta, R., Sabharwal, M., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_27_26
Vaitha, R., Lakha, A. S., D’Costa, J., Atife, M., Munro, J., Fateen, W., Barnes, E. J., & Gordon-Weeks, A. N. (2026) · Clinical Surgical Oncology · doi:10.1016/j.cson.2026.100136
Álvarez, M. N., Roca, J. J. M., Muñoz, R. C., Arbeloa, J. M. M., & Arévalo, A. G. (2026) · Revista Clínica de Medicina de Familia · doi:10.55783/rcmf.190206
Han, S., Shin, J., Kim, J. C., & Na, D. H. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00815-4
Pharmacologic management of metabolic and alcohol-associated liver disease
Pagadala, M., Jalil, S., Dunn, N., & Singal, A. K. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.29
Endocrinology at the epicenter of metabolic associated steatotic liver disease
Rubio, M. Á., & Martín, J. E. S. (2026) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2026.501847
Incretin-based therapy for MASH: are two better than one?
Sterling, R. K. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.74
Li, Y., Li, C., Li, Y., Guo, S., Liu, Y., Wei, S., Tong, T., He, H., Guo, C., & Zhang, N. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118169
Selecting Pharmacologic Interventions for MASH
Pan, J. J., Horwich, B., Chahine, M., Gutierrez, J. A., & Saab, S. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-10003-x
Lebererkrankungen als Komplikation des Diabetes mellitus
KAHL, S., & Huttasch, M. (2026) · Info Diabetologie · doi:10.1007/s15034-026-5273-x
“[7].”
Wang, Q., Zhang, B., Wang, Y., Xu, X., Zuo, K., Luo, J., Fan, H., Li, Z., Pan, H., & Jiang, S. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c09111
Rethinking sustained recompensation in MASLD cirrhosis: The value of pharmacological maintenance
Toshikuni, N., & Shimatani, M. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000984
Extracellular matrix proteins as risk markers for complications in type 1 diabetes
Rygg, M. O., MØLLER, A. L., Curovic, V. R., Rasmussen, D. G. K., Theilade, S., Tofte, N., Winther, S. A., Genovese, F., Karsdal, M. A., Kümler, T., et al. (2026) · Diabetic Medicine · doi:10.1111/dme.70396
Khalil, I., Sarker, P., Hossain, M. S., Chowdhury, A., Khalid, A. A., Saha, A., Chowdhury, J., Akter, M. M., Promi, S. A., Sayed, M. A., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.06.004
Medikamentöse Therapie der Leberzirrhose
Schachteli, F., Uschner, F. E., Trebicka, J., & Brol, M. J. (2026) · Gastroenterologie up2date · doi:10.1055/a-2358-8821
Are GLP-1 receptor agonists gerotherapeutics or just treatments for obesity?
Peyer, J. G. (2026) · Nature Aging · doi:10.1038/s43587-026-01165-4
Teli, B., Sathe, S., Kalra, R., Mahajan, V., Mehta, A., Shinde, R., Kunwar, B., Kahale, P., Sinkar, A., Palimkar, P., et al. (2026) · Cureus · doi:10.7759/cureus.111322
Janstová, K., Kyselová, D., & Trunečka, P. (2026) · Vnitřní lékařství · doi:10.36290/vnl.2026.047
Kim, S., Barthel, A., Smurzynski, M., & MacEwan, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71033
Amatya, R., Min, K. A., & Shin, M. C. (2026) · Pharmaceuticals · doi:10.3390/ph19060962
Małek, M., Denkiewicz, A., Denkiewicz, K., Pachulska, K., Dorosz, W., Podolak, M., Nawracaj, M., Miłkowska, M., Bartczak, J., & Sosiński, P. (2026) · Quality in Sport · doi:10.12775/qs.2026.60.72834
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
GLP-1 Receptor Agonists beyond Glycemic Control: Physiology and Pharmacological Evidence
Amate, P. (2026) · Open Journal of Pharmacology and Pharmacotherapeutics · doi:10.17352/ojpp.000029
Lee, J.-H., Yoo, J., Kim, S. G., & Kim, Y. S. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0043
Lonardo, A., Jamalinia, M., & Weiskirchen, R. (2026) · Livers · doi:10.3390/livers6050086 · Cited by 1
“In the Phase 3 ESSENCE trial, semaglutide improved MASH resolution and reduced fibrosis without worsening of steato-hepatitis [176].”
Lunati, M. E., Galesi, G., Bernasconi, D., Tinari, C., & Fiorina, P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1833794
Solís, R. S., Baeza-Zapata, A., & Negrete‐Najar, J. P. (2026) · Cureus · doi:10.7759/cureus.111728
“In addition, the phase 3 ESSENCE study demonstrated that semaglutide improved steatohepatitis resolution and fibrosis in patients with MASH and moderate-to-advanced fibrosis [26].”
Repercussões dos incretinomiméticos na dinâmica biliar e no parênquima hepático
Diniz, J. S., Pereira, G. D. L., Jardim, G. S., de Onofre, I. N., & Valle, T. I. (2026) · Congresso Médico Acadêmico UniFOA. · doi:10.47385/cmedunifoa.2737.2026
Leone, V., & Kennedy, A. J. (2026) · Journal of Clinical Investigation · doi:10.1172/jci207921
“while semaglutide, a glucagon-like peptide 1 receptor agonist, resolves MASH in roughly 60% of patients, with approximately 37% exhibiting improved fibrosis (4).”
Maevskaya, M. V., Okovityi, S. V., Бакулин, И. Г., Bidzhiev, A. S., Glushenkov, D. V., Gurova, O. Y., Gorshkov, A. Y., Амантаевна, Ж. В., Zolnikova, O. Y., Каримов, М. М., et al. (2026) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2026-36-3-7-20
Fouad, Y. M., AlNaamani, K. M., Alawadi, F., Hassani, A. A., Alkhalidi, N. M. F., Hotayt, B., Abaalkhail, F. A., Rouabhia, S., Abdulla, M., Altarrah, M. Y., et al. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2698115
“The 2.4 mg once-weekly regimen is the evidence-based recommended dose for MASH [12].”
InfluentialCiancimino, G., Pecorella, F., Viscardi, S. M., Mantia, C. L., Caserta, A., Pennisi, G., & Petta, S. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.19
Long-term lessons from MATCH01 macrophage therapy in cirrhosis
Ding, B., Yang, B., & Cao, Z. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.05.016
Shelukar, S., Venkatesh, A., McDermott, B., Gervase, J., Winte, M. F., Loh, R., & Halegoua-De Marzio, M. (2026) · The Medicine Forum
Alkhanafsa, M., & Wafi, J. (2026) · Archives of Advances in Biosciences · doi:10.22037/aab.v17i1.52378
Imaging-based fibrosis assessment and risk stratification in MASLD
Jin, S., Zhou, T., Jin, D., Xie, J., Sheng, G., Li, H., Li, G., Qin, C., & Gao, P. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1880238 · Cited by 1
Yang, H., Zhang, X., Zhou, D., Zou, J., Xu, L., Chen, M., Zhao, S., Dai, J., Wang, X., Du, X., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118225 · Cited by 1
Joshi, D. M. (2026) · Cureus · doi:10.7759/cureus.112135
GLP-1 and MASH: When weight loss isn’t the whole story
Long, M. T., Krarup, N., & Knop, F. K. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.06.005
Self-citationWu, J., Zheng, W., Qi, Q., He, C., Zhai, C., & Fan, H. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm51234 · Cited by 1
“[177,178,179,180,181,182,183,184,185,186]).”
InfluentialAddressing the Public Health Threat of Steatotic Liver Disease in Mexico
Garín, M. F. B., Barquera, S., Castro‐Narro, G., Ruiz‐Margáin, A., Macías‐Rodríguez, R. U., Agirre‐Garrido, L., Arellano, M., Ramírez-Butanda, E., Chalasani, N., & Lazarus, J. V. (2026) · Archives of Medical Research · doi:10.1016/j.arcmed.2026.103476 · Cited by 1
Pendrey, A., Sierra, J. A. R., Lobo, F. A. A., Herrera, E. J. R., Muñoz, Y. M. F., & Sevilla‐Martir, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03702-4
“Similarly, the ESSENCE trial reported resolution of steatohepatitis and improvements in biochemical parameters after 72 weeks of semaglutide 2.4 mg once weekly [65].”
InfluentialDhaou, C. B., Rom, O., & Orr, A. W. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101624
Srikanth, P., Ahmed, S., Kumari, A., Swadia, D., Rahaman, S., Shaik, K. M., Dey, S., Sharma, S. S., & Nandi, S. (2026) · Research Square · doi:10.21203/rs.3.rs-9950723/v1
Halupnik, A. J., & Sánchez, A. (2026) · Clinical Chemistry · doi:10.1093/clinchem/hvag077
Still, M. D., Gettelfinger, A., Akinditan, V. O., Syed, A., Eggert, A., Thornsberry, T., Ciricillo, J. A., Sharma, D., & Yeboah‐Korang, A. (2026) · ACG Case Reports Journal · doi:10.14309/crj.0000000000002232
Bandaranaike, R., Kewish, M. F., & Tarwater, S. (2026) · ASIDE Gastroenterology · doi:10.71079/aside.gi.071126795
Drug Development for MASH ‐Related Compensated Cirrhosis: Past, Present and Future
Zeng, R., Shao, Y. C., Lin, R.-T., Shen, X.-T., Sun, Q., Xin, X., Liu, P., Fan, J., Hu, Y., & Feng, Q. (2026) · Liver International · doi:10.1111/liv.70784 · Cited by 2
Toffoli, B., Sirignano, M., Bonato, V., Fusaro, G., Russo, E., Velardi, V., Crocè, L. S., Fabris, B., Candido, R., & Bernardi, S. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02976-3
Mantovani, A., & Targher, G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71110
Examining Aging Related Female Adiposity Through the Endocrine Lens
Gülşen, M. R., Pal, L., & Lathief, S. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-24097-2_6
Haidar, L., & Delaney, J. A. (2026) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000001059 · Cited by 1
The Biological Clock–Mitochondria Axis in the Liver: From Molecular Mechanisms to Metabolic Disease
Manuti, V., Murgo, E., Saponaro, A. A., Sfregola, U., Sangineto, M., Villani, R., Serviddio, G., Mazzoccoli, G., & Colangelo, T. (2026) · Biology · doi:10.3390/biology15141197
“REV-ERB α / β agonists, including SR9009 and SR9011, have demonstrated protective effects against hepatic steatosis, insulin resistance, inflammation, and fibrosis in diet-induced murine models of NASH, with efficacy that varies according to the time of administration [100].”
GDF15 in Liver Fibrosis: Molecular Mechanisms, Immunoregulatory Functions, and Therapeutic Potential
Gan, X., Zhang, L., Yu, T., Jin, S., Wu, Y., Xu, R., Zhang, Y., Zhang, J., Xu, L., & Wang, X. (2026) · Biomolecules · doi:10.3390/biom16071060
“…potential reversibility under certain conditions, recent FDA approvals, such as semaglutide in August 2025 and resmetirom in March 2024 for patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced fibrosis, highlight emerging therapeutic opportunities [7,8].”
Petta, S., Pennisi, G., Celsa, C., Messaoudi, S., Tsochatzis, E. A., Bugianesi, E., Yoneda, M., Zheng, M., Hagström, H., Boursier, J., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.07.006 · Cited by 1
Self-citationPharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations
Newsome, J. S. (2026) · Journal of Pharmacy Technology · doi:10.1177/87551225261466571
Metabolic Health: The Interplay Between NAFLD, MAFLD, MASLD, and Cardiovascular Disease
Różycka-Kosmalska, M., & Kosmalski, M. (2026) · Life · doi:10.3390/life16071197
“Fibrosis improvement: 36.8% vs. 22.4%; EDP 14.4% [48,49] All-criteria response (ALT + FAST + histology): 45.7% vs. 10.4% [48].”
InfluentialFATTY LIVER DISEASE – MODERN TRENDS IN EARLY DETECTION AND TREATMENT
Mitrović, B., Tomašević, R., & Gluvic, Z. M. (2026) · Taurunum Medical Journal · doi:10.63696/tmj202601005
Elkoshi, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1864104 · Cited by 1
“In the recent ESSENCE trial, 62.9% of patients receiving semaglutide achieved resolution of metabolic dysfunction-associated steatohepatitis without worsening of fi brosis at 72 weeks, compared to 34.3% in the placebo group (5).”
InfluentialSaigal, A., Abdurrachim, D., Tso, E., Hendra, C., Ong, C. Z. L., Kimball, S., Blumenschein, W. M., Liu, Y., Jiang, X., Sanyal, A. J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73370-z · Cited by 1
“Semaglutide, a GLP-1 receptor agonist, effectively reduced hepatic lipotoxic burden and improved MASH resolution 16,30 , as evidenced by signi fi cant improvements in NAS, steatosis, in fl am-mation, and ballooning scores (Fig.”
Self-citationTacke, F., Kim, Y., Haas, J. S., Daumont, M., Maas, C., O’Donnell, J., & Schattenberg, J. M. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2026-0092
Lawitz, E., Poordad, F. F., & Goodman, Z. D. (2026) · Liver International · doi:10.1111/liv.70808
Palasantzas, V. E. J. M., Struik, D., Bos, T., Koster, M. H., Gelderloos-Arends, J., Vos, E. R., van Dijk-Bos, K. K., Withoff, S., Fu, J., Hoogerland, J. A., et al. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.101069
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.06.013
Hishiki, T., Honda, A., Tanaka, R., Minomo, Y., Minamisawa, O., Konno, T., Kamata, S., Kamichatani, W., Tokuoka, S. M., Kita, Y., et al. (2026) · Biomolecules · doi:10.3390/biom16081078
“Numerous drugs targeting various molecular targets have been developed [1–4]; however, only two have been approved: resmetirom [5] and semaglutide [6].”
Luca, F. D., Troise, D. E., Camporeale, V., Leccese, G., Galloso, F., Cuttano, R., Infante, B., Stallone, G., Ranieri, E., & Netti, G. S. (2026) · Antioxidants · doi:10.3390/antiox15091116 · Cited by 3
“Semaglutide has demonstrated kidney outcome benefit in type 2 diabetes with CKD [201], while MASH data support activity across the broader metabolic disease axis [202].”
Ryaboshapkina, M., Gunnarsson, S., Whatling, A., Henry, I., & Azzu, V. (2026) · Research Square · doi:10.21203/rs.3.rs-10436396/v1
Tacke, F., Detjen, K. M., Heisig, J., & Hampe, J. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2890-7253
Horn, P., & Tacke, F. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01498-z
Khan, S. H., Jamal, A., Qadri, M., Zai, I. A., Shah, A., Ahmed, A., Khalid, A. A., Khan, A., Misbahuddin, F., Iftikhar, H., et al. (2026) · Medicine · doi:10.1097/md.0000000000049916
“This meta-analysis combined 4 RCTs: Flint et al, [25] Newsome et al, [26] Loomba et al, [27] and Sanyal et al. [28] The included trials were conducted in multiple countries, with durations ranging from 48 to 72 weeks.”
Optimizing GLP-1 Receptor Agonist Use: Mechanisms, Clinical Applications, and Safety Profiles
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8391-3
Ye, C., Zhang, Z. K., Ding, Y., Yu, Y., Zhang, S., Pan, J., Nie, S., Li, S., Zhang, L. R., Lu, L., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71113
Beyond Fat: Reframing MASLD Through Genetics, Clonal Biology, and Precision Hepatology
Crespo, J., Alonso‐Peña, M., Jiménez-González, C., Cayon, L., & Iruzubieta, P. (2026) · Pharmaceuticals · doi:10.3390/ph19081145
“The emergence of therapies directed against PNPLA3 and HSD17B13, together with the accelerated approval of resmetirom and semaglutide, further reinforces the biological plausibility of this transition and progressively aligns MASLD with precision medicine models already established in oncology and…”
Chagas, Y. C. M., Koga, J. Y. V., Kuniyoshi, A. S. O., & Gasparin, F. R. S. (2026) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2026v8n7p943-963
McGovern, A., Cinfio, F. N., & Luo, R. (2026) · PharmacoEconomics · doi:10.1007/s40273-026-01647-8
Gwak, S. (2026) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2026.8.e8
Sun, S., Wang, C., Yuan, M., & Min, H. (2026) · Hepatology International · doi:10.1007/s12072-026-11132-1
Zhu, S., Yang, F., Lu, H., Jiang, J., & He, W. Q. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1843719
“Semaglutide also has high-level evidence, as phase 3 data demonstrated significant histological benefit in MASH with F2 – F3 fibrosis, and GLP-1 receptor agonist therapy has additional evidence for cardiovascular risk reduction in high-risk obesity or diabetes population (154, 155).”
Boulet, J., & O’Meara, E. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.07.369
García-Pérez, R., Siles-Guerrero, V., Elhadri-Egea, A., Maroto, G. P., Guardia-Baena, J. M., Hayón-Ponce, M., López-de-la-Torre-Casares, M., Muñoz‐Garach, A., & Romero‐Márquez, J. M. (2026) · Endocrines · doi:10.3390/endocrines7030039
“Consequently, therapeutic strategies such as semaglutide, which simultaneously improve glucose homeostasis, promote weight loss, and reduce hepatic steatosis, may offer a dual clinical benefit [18,19].”
Caponio, D., Acucella, G. A., & Acucella, M. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02759-5 · Cited by 1
Shi, Y., Han, Y., Zhang, H., Zhang, Y., Wei, W., Xu, W., Bao, X., & Lu, C. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158653
Upadhyay, R., TIWASKAR, M. H., Saboo, B., Sreenivasamurthy, L., Sonawale, K., Prajapati, C., & Muralidharan, P. (2026) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1501
“25 This resulted in the USFDA approving semaglutide too, for the management of MASH.”
Guo, S., Liu, B., Li, H., Yu, Y., & Xu, J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1878927
“…resmetirom, a liver-directed thyroid-hormone-receptor-β agonist and the first agent approved for MASH with fibrosis (61), and incretin-based therapies (the GLP-1 receptor agonist semaglutide and the dual GIP/GLP-1 agonist tirzepatide) that improve steatohepatitis in randomized trials (62, 63).”
Kim, G.-H., Rho, H., Lee, C. H., Hong, Y.-J., Park, Y. R., Yu, H. C., Song, M.-Y., Jo, H. J., Kang, E. J., Han, R., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02796-0 · Cited by 1
“…and semaglutide have recently been approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with fi brosis, 8 – 11 effective therapeutic strategies that directly and robustly target liver fi brosis and cirrhosis remain limited, indicating that a substantial…”
Adipose Tissue Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease
Cruz, A. J. L., & Yuan, L. (2026) · Cells · doi:10.3390/cells15151377 · Cited by 1
“Phase 3 results for semaglutide in MASH were published in 2025, and FDA approval of Wegovy for non-cirrhotic MASH with moderate-to-advanced fibrosis followed in August 2025 [97,98].”
InfluentialSoloveva, A. E., Park, J. J., Apostolou, E., Böhm, M., Cannata, A. N., Fudim, M., Kittipibul, V., Mueller, S., Potapova, K., Schattenberg, J. M., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag243
Leung, H.-K., Tan, G.-J., Wong, W., Khamis, F., Zain, S. M., & Chan, W. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.20
Liver muscle bone axis in metabolic dysfunction-associated steatotic liver disease
Binhua, L., Zhang, Y., Can, Z. H. O. U., Cao, H., & Zeng, J. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.113 · Cited by 1
Zhang, C., Song, Y., Huang, Y., Luo, Y., Zhao, H., Huang, Y., Zhao, H., & Qiu, Z. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158673 · Cited by 1
Metadata
- Authors
- Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V.
- Affiliations
- Virginia Commonwealth University (US)
- King's College London (GB)
- Novo Nordisk (Denmark) (DK)
- University of Turin (IT)
- University of Chicago (US)
- Düsseldorf University Hospital (DE)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-05
- Volume
- 392
- Issue
- 21
- Pages
- 2089-2099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4409963211
- Cited by
- 1,115
- References
- 39
- Citations by year
- 2026: 813 · 2025: 302
- FWCI
- 767.51
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, nonalcoholic steatohepatitis, GLP-1 receptor agonists, liver fibrosis, weight loss, body mass index, non-alcoholic fatty liver disease, fibrosis regression, interim analysis, multiple testing correction, non-invasive fibrosis markers
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Biopsy, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.